Elaine Shum

Nemvaleukin alfa, a novel engineered IL-2 fusion protein, drives antitumor immunity and inhibits tumor growth in small cell lung cancer

Kwok-Kin Wong, V. Velcheti, Hsin-Yi Huang, 2022, Journal for ImmunoTherapy of Cancer.

Extended Survival in Patients With Non–Small-Cell Lung Cancer–Associated Brain Metastases in the Modern Era

D. Kondziolka, J. Golfinos, V. Velcheti, 2023, Neurosurgery.

Berzosertib Plus Topotecan vs Topotecan Alone in Patients With Relapsed Small Cell Lung Cancer: A Randomized Clinical Trial.

M. Aladjem, J. Riess, C. Redon, 2023, JAMA oncology.

The Common Thread: A Case of Synchronous Lung Cancers and a Germline CHEK2 Mutation.

Fang Zhou, J. Sabari, E. Shum, 2021, Clinical lung cancer.

Immunotherapy in non-small cell lung cancer: Past, present, and future directions

V. Velcheti, S. Punekar, S. Lau, 2022, Frontiers in Oncology.

TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation

S. Chanda, M. Weirauch, D. Kaufman, 2021, Cell.

Entinostat plus Pembrolizumab in Patients with Metastatic NSCLC Previously Treated with Anti–PD-(L)1 Therapy

P. Jänne, E. Schmidt, S. Ramalingam, 2020, Clinical Cancer Research.

Selective Personalized RadioImmunotherapy for Locally Advanced Non–Small-Cell Lung Cancer Trial (SPRINT)

S. Jolly, B. Halmos, S. Gadgeel, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey.

M. Garassino, V. Sriuranpong, J. Tanizaki, 2024, Lung Cancer.

In vivo metabolomics identifies CD38 as an emergent vulnerability in LKB1-mutant lung cancer

C. Rudin, H. Ji, B. Neel, 2023, bioRxiv.